Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma
Hepatitis C virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma
复制标题
DOI：
10.1016/j.jiac.2016.12.008
复制
发表时间：
2017-05-01
影响因子：
2.2
通讯作者：
Kato, Junji
中科院分区：
文献类型：
--
作者：
Kawano, Yutaka;Miyanishi, Koji;Kato, Junji
在接受免疫抑制剂或抗癌药物治疗的患者中，与B型肝炎病毒再激活相比，丙型肝炎病毒（HCV）再激活相对罕见。在这里，我们提出了第一例基因型2型HCV再激活由于止吐类固醇治疗肝细胞癌（HCC）化疗期间，这是验证了不仅增加病毒载量，但在HCV再激活肝损伤的病理恶化。HCC的进一步化疗可以继续，无需类固醇治疗。本病例强调了对HCV再激活的认识和对复杂情况的管理。(C)2016年日本化疗学会和日本传染病协会。由爱思唯尔有限公司出版。保留所有权利。
Hepatitis C virus (HCV) reactivation is relatively rare compared with hepatitis B reactivation in patients treated with immunosuppressive or anticancer drugs. Here, we present the first case of genotype 2 HCV reactivation due to antiemetic steroid therapy during chemotherapy for hepatocellular carcinoma (HCC), which was verified by not only increased viral load but also pathological exacerbation of liver injury during HCV reactivation. Further chemotherapy for HCC could be continued without steroid therapy. This present case highlights the awareness of HCV reactivation and the management of complex situation. (C) 2016 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.